meperizumab

**Meperizumab** is a proposed monoclonal antibody biosimilar to **mepolizumab** referencing **Nucala**. Publicly verifiable evidence from a registered Phase 1 study shows it was developed by **Chia Tai Tianqing Pharmaceutical Group** for pharmacokinetic and safety similarity testing versus Nucala in healthy male volunteers. Based on its reference product, meperizumab is intended to act as an **interleukin-5 neutralizing antibody**, thereby reducing eosinophilic inflammation; however, the public evidence located here is centered on biosimilarity evaluation rather than a detailed independent nonclinical or clinical mechanism package for meperizumab itself.

Other names

meperizumabMeperizumab injection